[2015-Mar-06] FDA approves new antifungal drug Cresemba
http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm437106.htm
Cresemba.cdxPeter A. Warn, Andrew Sharp and David W. Denning, In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp., J. Antimicrob. Chemother., 2006, 57 (1), pp 135-138
http://dx.doi.org/10.1093/jac/dki399
Anne Schmitt-Hoffmann, Brigitte Roos, Jürgen Maares, Markus Heep, Jochen Spickerman,
Erhard Weidekamm, Tom Brown and Michael Roehrle, Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers, Antimicrob. Agents Chemother., 2006, 50 (1), pp 286-293
http://dx.doi.org/10.1128/AAC.50.1.286-293.2006
H. Seifert, U. Aurbach, D. Stefanik and O. Cornely, In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream Isolates, Antimicrob. Agents Chemother., 2007, 51 (5), pp 1818-1821
http://dx.doi.org/10.1128/AAC.01217-06
A. C. Pasqualotto and D. W. Denning, New and emerging treatments for fungal infections, J. Antimicrob. Chemother., 2008, 61 (suppl. 1), pp i19-i30
http:/dx.doi.org/10.1093/jac/dkm428
Corrado Girmenia, New generation azole antifungals in clinical investigation, Expert Opin. Investig. Drugs, 2009, 18 (9), pp 1279-1295